# A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder.

> **NCT01197508** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 696 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** TC-5214
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01197508
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 696 (ACTUAL)
- **Last updated:** 2014-04-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01197508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01197508, "A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder.". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01197508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*